DrugPatentWatch Database Preview
Drugs in Development Information for Huperzine-A
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for Huperzine-A?
Huperzine-A is an investigational drug.
There have been 10 clinical trials for Huperzine-A.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Alzheimer Disease, Schizophrenia, and Cognition Disorders. The leading clinical trial sponsors are Shanghai Mental Health Center, National Institute on Aging (NIA), and Baylor College of Medicine.
Summary for Huperzine-A
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2009-12-01) |
| Vendors | 25 |
Recent Clinical Trials for Huperzine-A
| Title | Sponsor | Phase |
|---|---|---|
| Effects of Hearing Rehabilitative Interventions and Huperzine A on Presbycusis(Δ,kHz, dB,MMSE, AD) | Zhijun Bao | N/A |
| Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging | Shanghai Mental Health Center | Phase 4 |
| Effects of Huperzine A in Treatment of Moderate to Severe TBI | Spaulding Rehabilitation Hospital | Phase 2 |
Clinical Trial Summary for Huperzine-A
Top disease conditions for Huperzine-A
Top clinical trial sponsors for Huperzine-A
US Patents for Huperzine-A
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
